NCT00759876View on ClinicalTrials.gov

Phase 2a Extension Study of Ataluren (PTC124) in Duchenne Muscular Dystrophy (DMD)

PHASE2TerminatedINTERVENTIONAL
Enrollment

36

Participants

Timeline

Start Date

August 13, 2008

Primary Completion Date

May 17, 2010

Study Completion Date

May 17, 2010

Conditions
Duchenne Muscular Dystrophy
Interventions
DRUG

Ataluren

Ataluren will be provided as a vanilla-flavored powder to be mixed with milk. Dosing based on participant body weight

Trial Locations (3)

19104

Children's Hospital of Philadelphia, Philadelphia

84112

University of Utah, Salt Lake City

45229-3039

Cincinnati Children's Hospital Medical Center, Cincinnati

Sponsors

Lead Sponsor

PTC Therapeutics
All Listed Sponsors
collaborator

Genzyme, a Sanofi Company

INDUSTRY

lead

PTC Therapeutics

INDUSTRY